Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy
- PMID: 12468915
- DOI: 10.1097/00043426-200212000-00011
Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy
Abstract
This study was designed to determine if low doses of oral sodium phenylbutyrate (SPB) induce hemoglobin F (HbF) synthesis in children with hemoglobin SS (HbSS). We treated 8 children with HbSS over a period of 5-30 weeks. The initial dose (1.0 g/d) was increased weekly (by 1.0 g/d) until F-reticulocytes doubled. All patients showed an increase in F-reticulocytes (P = 0.002) that was dose-dependent (P = 0.001). Three of 5 patients who continued oral SPB for more than 10 weeks had substantial increases in HbF. We conclude that lower dose SPB is effective in inducing HbF synthesis in some children with HbSS. Further trials are warranted to determine the optimal treatment regimen.
Comment in
-
Search for improved therapy of sickle cell anemia.J Pediatr Hematol Oncol. 2002 Dec;24(9):700-3. doi: 10.1097/00043426-200212000-00002. J Pediatr Hematol Oncol. 2002. PMID: 12468906 Review. No abstract available.
Similar articles
-
Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia.Pediatr Blood Cancer. 2008 Feb;50(2):357-9. doi: 10.1002/pbc.21104. Pediatr Blood Cancer. 2008. PMID: 17253639
-
Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate.Blood. 1994 Jul 1;84(1):339-43. Blood. 1994. PMID: 7517215
-
Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.Semin Oncol. 1992 Jun;19(3 Suppl 9):67-73. Semin Oncol. 1992. PMID: 1379375
-
Hydroxyurea induction of fetal hemoglobin synthesis in sickle-cell disease.Semin Oncol. 1992 Jun;19(3 Suppl 9):61-6. Semin Oncol. 1992. PMID: 1379374 Review.
-
Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.Adv Pediatr. 1996;43:309-34. Adv Pediatr. 1996. PMID: 8794181 Review. No abstract available.
Cited by
-
Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.Mol Cancer. 2008 Mar 6;7:24. doi: 10.1186/1476-4598-7-24. Mol Cancer. 2008. PMID: 18325101 Free PMC article.
-
The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response.J Lipid Res. 2009 Dec;50(12):2486-501. doi: 10.1194/jlr.M900216-JLR200. J Lipid Res. 2009. PMID: 19461119 Free PMC article.
-
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.Am J Hematol. 2012 Nov;87(11):1017-21. doi: 10.1002/ajh.23306. Epub 2012 Aug 7. Am J Hematol. 2012. PMID: 22887019 Free PMC article. Clinical Trial.
-
Radioprotection by the histone deacetylase inhibitor phenylbutyrate.Radiat Environ Biophys. 2011 Nov;50(4):585-96. doi: 10.1007/s00411-011-0384-7. Epub 2011 Sep 3. Radiat Environ Biophys. 2011. PMID: 21892632
-
The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.Blood. 2015 Jul 16;126(3):386-96. doi: 10.1182/blood-2015-02-626259. Epub 2015 Jun 1. Blood. 2015. PMID: 26031919 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical